Address
1000 Park Forty Plaza
Durham, NY 27713
United States of America (the)
Phone
917 580 3099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
315
First IPO Date
June 21, 2019
| Name | Title | Pay | Year Born |
| Eric Venker | Chief Executive Officer & Director | 1.15M | 1987 |
| Khira Gabliani | Chief of Staff to the CEO | 0 | N/A |
| Frank Torti | Executive Chairperson of the Board | 92,500 | 1979 |
| Tiago Girao | Chief Financial Officer | 691,212 | 1979 |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | 757,089 | 1975 |
| Jay S. Stout | Chief Technology Officer | 757,675 | 1963 |
| Melanie Gloria | Chief Operating Officer | 759,066 | 1978 |
| Ruby Grewal | Senior Vice President of Commercial | 0 | N/A |
| Luciano Pollastrini | Senior Vice President of CMC Technical Operations | 0 | N/A |
| Becky Merlina | Senior VP & Global Head of Quality | 0 | N/A |
| Lorna Liganor | Senior Vice President of Clinical Operations | 0 | N/A |
| Sheetal Patel | Senior Vice President of Clinical Development | 0 | N/A |
| Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management | 0 | N/A |
| Christine Blodgett | Senior Vice President of Human Resources | 0 | N/A |
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.